Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Populatation health, health equity, public health

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-02-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON CANADIAN DRUGS AND SUBSTANCES STRATEGY

December 1, 2018
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and 
standardized appearance)
https://policybase.cma.ca/link/policy13930

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-09-06</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE: Response to consultation
DATE: 2018-07-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Mr. Komper,

The Canadian Medical Association (CMA) appreciates the opportunity to provide comments on the proposed Front-of-Package Labelling (FOPL) framework for Food Products and Beverages. The CMA expresses support for the adoption of FOPL on foods and non-alcoholic beverages, which have been shown to improve health outcomes through population-level changes in food and beverage consumption. FOPL can complement other strategies, such as tax increases, to promote healthy eating behaviors and reduce population health risks associated with elevated intake of sugar-sweetened beverages and high-sodium foods.

The CMA believes that the federal government’s proposed regulation approach is a positive step in encouraging healthier food choices. FOPL can serve as an additional tool to inform consumers about the nutritional content of products, thereby helping them make healthier choices when shopping.

The CMA supports the implementation of the proposed framework on the front-of-package, ensuring that it is presented in a clear and accessible manner. The CMA notes that the proposed approach aligns with existing regulations and public health guidelines.

The CMA encourages the federal government to consider incorporating feedback from stakeholders during the implementation phase to ensure the effectiveness of the FOPL framework.

Sincerely,

Canadian Medical Association
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE
Response to consultation

DATE
2018-01-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE  2017-12-07
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE Response to consultation
DATE 2017-11-7
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE Response to consultation
DATE 2017-06-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE: Response to consultation
DATE: 2017-04-05

TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
   Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Chief Statement - Application d’Études

Cannabis is a complex and challenging issue that requires a comprehensive approach. The Canadian Medical Association (CMA) has been actively involved in the development of policies and guidelines to address the health and social implications of cannabis use.

The health impact of cannabis use is multifaceted and can vary depending on the context and individual factors. Research has shown that cannabis use can lead to a range of health issues, including respiratory problems, mental health concerns, and addiction.

The CMA recommends that any policy on cannabis should prioritize public health and safety. This includes the implementation of evidence-based policies that are designed to minimize harm and promote the well-being of Canadians.

The CMA supports the decriminalization of cannabis as a step towards addressing the health and social implications of cannabis use. This would allow for a more comprehensive approach to addressing the issues associated with cannabis use.

The CMA recommends that any policy on cannabis should prioritize public health and safety. This includes the implementation of evidence-based policies that are designed to minimize harm and promote the well-being of Canadians.

The CMA supports the decriminalization of cannabis as a step towards addressing the health and social implications of cannabis use. This would allow for a more comprehensive approach to addressing the issues associated with cannabis use.

For more information, please contact: 1-888-454-9111

Canadian Medical Association

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  Response to consultation
DATE        2016-08-12
TOPICS       Health care and patient safety
             Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016
Dave Chilton
Deputy Minister
Pricing, Pricing Policy & Regulatory Affairs
Health Canada
Ottawa, Ontario
August 12, 2016

Dear Colleague,

The Canadian Medical Association (CMA) is pleased to respond to the consultation on Health Canada’s Consultation on “Plain and Standardized Packaging” (the “Consultation”).

CMA is supportive of the Consultation’s goal to reduce demand for tobacco use in Canada and the role that packaging plays in combating tobacco use. CMA believes that government should support evidence-based policies to reduce tobacco use and that plain and standardized packaging is an important step in this direction.

CMA recommends that the government consider the following recommendations:

1. Implement plain and standardized packaging for tobacco products to reduce tobacco consumption.
2. Provide funding to support public health campaigns to educate the public about the health risks of tobacco use.
3. Support tobacco control research to better understand the impact of plain and standardized packaging on tobacco use.

CMA looks forward to working with Health Canada and other stakeholders to implement evidence-based policies to reduce tobacco use in Canada.

Sincerely,

[Signature]

Deputy Minister, Pricing, Pricing Policy & Regulatory Affairs
Health Canada

CMA Policybase - Canadian Medical Association
Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/link/policy11847

**POLICY TYPE**
Response to consultation

**DATE**
2016-03-19

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

**POLICY TYPE**
Response to consultation

**DATE**
2016-01-20

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

**Documents**

[Image of document page]
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

**POLICY TYPE**  
Response to consultation

**DATE**  
2015-06-08

**TOPICS**  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2014-08-26</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents